Guoxin Pharma Secures Nearly RMB 100 Million in Series B+ Financing to Accelerate End-to-End Cell and Gene Therapy (CGT) CRO Platform Development

VCBeat (WeChat: vcbeat) has learned that recently, the clinical CRO company Guoxin Pharmaceutical Technology(Beijing)Co., Ltd.（(Guoxin Pharmaceutical) announced the completion of a Series B+ financing round amounting to nearly RMB 100 million. In this round, existing shareholder Yuepin Medical Fund continued to increase its investment, while prominent industry investors—including Guangzhou High-Tech Industrial Development Zone Group’s Guangzhou Guoju Venture Capital, Shenzhen Qianhai Beizeng Assets, Zhongguancun Bank Technology Finance Center, and Ruize (Guangzhou) Investment—jointly participated. This Series B+ financing marks another funding milestone for Guoxin Pharmaceutical in 2022, following its Series B round in August 2021 led by Puhua Capital and Jinhui Feng Investment, among others.

Guoxin Pharmaceutical, established in 2008, is a renowned name in China’s clinical CRO industry. Committed to becoming the most trusted global R&D partner for pharmaceutical companies both domestically and internationally, the company adheres to the philosophy of “making clinical research more professional, efficient, and reliable.” It specializes in providing comprehensive solutions for clinical study registration and regulatory submissions for innovative drugs and novel cell and gene therapy (CGT) products. Guoxin Pharmaceutical has been honored as one of the Top 20 National Pharmaceutical R&D Service Outsourcing Companies for three consecutive years and is recognized as both a National High-Tech Enterprise and a Zhongguancun High-Tech Enterprise.

The core management team of Guoxin Pharmaceutical comprises seasoned medical and operational executives from multinational corporations such as Novartis, Takeda, Parexel, PRA, and INC, delivering high-quality services to pharmaceutical groups and leading innovative biotech companies.Guoxin Pharmaceutical has established in-depth collaborations with over 1,200 Grade A tertiary hospitals, more than 900 clinical research institutions, and over 300 pharmaceutical companies across China, having completed more than 500 clinical trials to date.

Since 2020, Guoxin Pharmaceutical has focused on providing clinical CRO services for innovative drugs, cell and gene therapies, and rapidly established an integrated innovation service translation platform encompassing cell therapy, gene therapy, oncolytic viruses, antibody-drug conjugates (ADCs), and nucleic acid-based therapeutics. Prioritizing the development of advanced therapy technologies, Guoxin Pharmaceutical has taken a leading position in areas such as cell and gene therapy products and nucleic acid-based drugs. By building an innovation service translation platform and cultivating an industrial ecosystem, it has become a leading clinical CRO in China’s cell and gene therapy (CGT) sector.

Guoxin Pharmaceutical has established a leading one-stop service capability for empowering clinical research of innovative drugs, and has now become a leading CRO in the field of cell and gene therapy (CGT) in China, undertaking registration applications and clinical research tasks for multiple cutting-edge pipelines.Guoxin Pharmaceutical’s current pipeline encompasses a variety of cell and gene therapy (CGT) modalities, including CAR-NK, CAR-T, TCR-T, RAK, TIL, stem cells, iPSCs, and AAV-based gene therapies. The company has accumulated extensive experience in global regulatory submissions and clinical research programs.Meanwhile, the company is actively expanding its international clinical research business, gaining a deep understanding of the supply chain and market value of the innovative drug R&D industry, thereby facilitating the successful global expansion of China’s biopharmaceutical sector. Currently, the company is experiencing rapid growth in new orders for innovative drugs, with a particularly significant surge in orders within the cell and gene therapy (CGT) sector, driving strong performance growth.

With the support of the capital market, Guoxin Pharmaceutical will continue to improve its internal controls and corporate governance framework, establishing a scientific management system and governance structure. Following the completion of this round of financing, the company will remain focused on deepening clinical research into innovative drugs within its advanced pipeline, further integrating business and technology, and continuing to highlight its competitive advantages in the field of cell and gene therapy (CGT). As the projects funded by this round are gradually implemented, the company will continuously optimize its industrial chain layout, expand its business and profit scale, and build a large-scale medical and operational team aligned with international standards, thereby providing strong support for the translation of biomedical innovations.

Chen Yongqing, Founder and Chairman of Guoxin Pharmaceuticalstated: “We extend our sincere gratitude to both new and existing strategic investors—including Guangzhou High-Tech Industrial Development Zone Group’s Guoju Capital, Shenzhen Qianhai Investment, Zhongguancun Bank’s Technology Finance Center, Ruize (Guangzhou) Investment, and the returning shareholder Yueyin Medical Fund—for their strong recognition and trust in Guoxin Pharmaceutical. These institutional investors all possess profound and professional industry insights, along with an investment philosophy that balances rationality with optimism. We believe that, leveraging this round of financing, Guoxin Pharmaceutical will build upon its strengths—such as an outstanding international talent team, unique technological advantages, and years of successful project experience—to work hand in hand with clients and partners in achieving more key milestones in the field of cell and gene therapy. In the future, we will continue to refine and optimize our corporate management system, enhance our market expansion capabilities both domestically and internationally, and deliver exceptional CRO services to global customers through an open, innovative, and quality-reliable service transformation platform, thereby making effective medicines accessible to the public at an earlier stage. Guoxin Pharmaceutical will continue to deepen and leverage its dual-wheel drive advantage of capital and business operations, striving to become a leading CRO enterprise in the cell and gene therapy sector.”

Guangzhou High-Tech Industrial Development Zone Groupstated: “We welcome Guoxin Pharmaceutical to develop its business in our district. Guangzhou High-Tech Investment Group is rooted in the Huangpu District and Development Zone of Guangzhou, with a strategic focus on the development and construction of the biopharmaceutical industry. We look forward to further deepening cooperation with Guoxin Pharmaceutical in the field of cell and gene therapy (CGT), jointly empowering enterprises in the Greater Bay Area and advancing clinical development in the CGT sector.”

Cheng Zhipeng, General Manager of Shenzhen Qianhai Beizeng Asset Managementstated: “Guoxin Pharmaceutical boasts a professional and efficient operational team, a reputable industry standing, and extensive clinical resources accumulated over many years, having established competitive service capabilities in the field of clinical research for innovative drugs such as gene and cell therapies (GCT). We are pleased to participate in this round of investment in Guoxin and look forward to its role in bringing more high-quality innovative drugs to market in the future.”

An Yang, Director of the Technology Finance Center at Zhongguancun Bankstated: “Guoxin Pharmaceutical boasts profound industry expertise, keen insight into emerging trends, abundant clinical resources, and strong comprehensive client service capabilities. Its talent pool in related industries helps support the company’s long-term, sustainable business development.”

CGT drugs target the upstream of biological genetic information, theoretically covering all diseases caused by protein abnormalities. Currently marketed CGT drugs have demonstrated strong market performance, filling supply gaps for rare diseases on one hand and effectively enabling long-term therapeutic efficacy on the other. They possess advantages that are difficult to match with traditional small-molecule chemical drugs and large-molecule biologics, which has significantly stimulated enthusiasm for drug R&D. In the long run, CGT is expected to lead the innovative drug industry chain through a paradigm shift.

Currently, most cell and gene therapy (CGT) drugs are in the early stages of clinical development. The mismatch between supply and demand remains the core contradiction within the industry chain; leading companies have full order books, while high-quality production capacity remains scarce. The entry of industrial policies into a standardized development phase has provided a supportive policy environment for the research, development, and manufacturing of innovative drugs. It is believed that the deployment of specialized technologies and therapies will inevitably unlock incremental growth opportunities. The trajectory of technological innovation ultimately evolves toward broader public accessibility. With technological iterations and upgrades, coupled with the optimization and maturation of manufacturing processes expected to reduce drug production costs, the commercial potential of CGT drugs will be fully realized. Consequently, the expansion of the contract research, development, and manufacturing organization (CXO) market demonstrates high certainty and strong sustainability.

Wang Hongtao, Director of Ruizhe (Guangzhou) Investmentstated: “From a developmental perspective, the cell and gene therapy sector holds immense potential for future growth. Guoxin Pharmaceutical is a leading domestic provider of top-tier clinical research services in the field of cell and gene therapy, boasting an experienced and internationalized team of experts. We are delighted to participate in this round of financing for Guoxin Pharmaceutical and look forward to collaborating with them to expand into both domestic and international markets, serve global cell and gene therapy enterprises, jointly advance the development of the cell and gene therapy industry, and benefit more patients.”

Xiong Shuirou, Partner at Yueyin Medical Fund and Existing Shareholderstated: “As one of the early-stage investors in Guoxin Pharmaceutical, we are delighted to see the company maintain rapid growth under the leadership of Dr. Chen Yongqing, building a highly efficient and professional team that is at the forefront of the industry in innovative fields such as cell and gene therapy (CGT), thereby further earning recognition from leading investment and industrial institutions within the sector. Yueyin Medical Fund will continue to support Guoxin Pharmaceutical’s development. In this new cycle of pharmaceutical innovation, we look forward to seeing greater enhancements in Guoxin Pharmaceutical’s innovation capabilities and global layout, so as to provide patients with more novel, high-quality innovative medicines.”